By 2026-06-10T09:22:00+01:00
AI has attracted enormous investment across drug discovery, but major questions still remain around validation, reproducibility and real-world application. In our latest Beyond the Lab report, experts discuss where the technology is starting to influence discovery workflows – and where limitations continue to slow adoption.
Artificial intelligence is now being applied across multiple areas of drug discovery, with researchers using AI to identify targets, design molecules, analyse biological data and support early-stage decision-making.
As investment in pharmaceutical AI continues to accelerate, companies working across drug discovery are under increasing pressure to demonstrate where these technologies can improve discovery workflows – and where limitations continue to affect adoption.
This report explores how AI is being applied across early drug discovery, giving readers a clearer understanding of where these technologies are influencing discovery workflows and the challenges that still remain.
Register to access the full report and explore where AI is delivering value across drug discovery workflows – and why challenges around adoption still remain.
2026-06-10T09:11:00Z
2026-06-08T09:00:00Z
2026-06-04T09:00:00Z
2026-06-03T07:30:00Z
2026-06-02T09:00:00Z
2026-06-01T09:00:00Z
2025-08-05T13:42:00
2026-05-05T13:24:00
2026-06-02T15:00:00 2026-06-02T16:00:00
2026-06-01T07:00:00
2024-02-01T12:06:43
2025-06-02T10:00:00
2026-05-05T13:24:00Z
2026-03-31T09:16:00Z
2025-11-04T09:14:00Z
2025-08-05T13:42:00Z
Site powered by Webvision Cloud
